Aurealis Therapeutics Enhances Board of Directors Expertise by Appointing Tuomo Pätsi as New Member

Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, is pleased to announce the appointment of Tuomo Pätsi as a new member of its Board of Directors. Mr. Pätsi’s election was confirmed on June 18, 2024 during Aurealis Therapeutics’ Annual General Meeting. Existing Board Directors Silvio Inderbitzin, Jean de Gunzburg, Juha Yrjänheikki and Laurent Décory were elected to continue along with Roger Meier as the Chairman of the Board.

Tuomo Pätsi is a distinguished biopharmaceutical industry executive, bringing over 30 years of experience from leading global companies. His most recent role was as Executive Vice President Commercial International and member of the Executive Committee of Seagen Inc. Prior to this, he served as President Worldwide Markets at Celgene Inc. Mr. Pätsi has held various leadership roles at Celgene, Human Genome Sciences, and Amgen. His expertise spans optimizing clinical strategy, achieving successful global commercialization, and enhancing pricing, access, and reimbursement strategies.

Mr. Pätsi is a registered pharmacist and holds an MSc in pharmacology from Helsinki University. Following his executive career, he has been actively involved as an advisor and board member for several healthcare companies. He is a co-founder of Rigi Therapeutics AG, chairman of the board of directors for Faron Pharmaceuticals Ltd, Notable Inc., and Phi Pharma AG, and a board member of Aqsens Health, Psyon Games, and now, Aurealis Therapeutics.

“I am thrilled to join Aurealis Board at this exciting time for the company, with the lead asset AUP-16 in phase 2, approaching clinical proof of concept. AUP-16 has the potential to address a very significant unmet medical need and help numerous patients across the world. The scientific platform and expertise at Aurealis also positions the company well to develop further products such as AUP-55 in cancer, and in other therapeutic areas. Personally, even if I have lived most of my professional life abroad, notably in Switzerland, my roots are in Finland, and I look forward to supporting the Swiss-Finnish collaboration in building a successful future for Aurealis,” said Tuomo Pätsi.

Juha Yrjänheikki, CEO of Aurealis Therapeutics, welcomed Mr. Pätsi, stating, “We are delighted to have Tuomo joining our Board of Directors. His extensive experience in commercialization and navigating the marketing authorization process will be invaluable as we advance AUP-16, our lead candidate for the healing of non-healing diabetic foot ulcers, currently in phase 2 clinical trials. Tuomo’s understanding of both the specificities of small biotechs and the dynamic of large companies will be key to strengthening Aurealis Therapeutics as we continue to progress AUP-16 in chronic wounds and expand our pipeline into cancer and inflammation.”

About AUP-16

AUP-16 is a genetically engineered Lactococcus Cremoris, a non-pathogenic, probiotic bacteria, expressing human basic fibroblast growth factor (FGF2, bFGF), interleukin-4 (IL4) and macrophage colony stimulating factor (CSF1, mCSF) – all in one product and accepted as one active pharmaceutical ingredient from regulatory perspective. AUP-16 is topically applied on chronic wounds and covered by wound dressing (e.g. in diabetic foot ulcers, venous leg ulcers and pressure ulcers). In the wound AUP-16 acts as millions of bioreactors producing the therapeutic proteins, which are designed to i) halt chronic inflammation in the wound, ii) induce growth of new blood vessels, and iii) promote granulation tissue formation and skin re-epithelization – all in one product.

About Aurealis Therapeutics

Aurealis Therapeutics AG is a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer. The company’s lead clinical assets are the first-in-class four-in-one cell and gene therapies AUP-16 for chronic wounds and AUP-55 for cancers. Aurealis therapies are based on proprietary technology involving genetically engineered Lactococcus Cremoris acting as millions of small immune-activating bioreactors producing multiple human therapeutic proteins (cytokines, growth factors, antibody fragments) to effectively and safely re-educate the distorted host immune microenvironment to a proper state.

For more information:

Laurent Décory, COO

Email: laurent@aurealistherapeutics.com

Share the news:

other recent news:

Aurealis Therapeutics Concludes Successful Partnering Week in China

Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, announced the successful completion of its partnering visit to China from 13-17 May, 2024. The week-long visit, led by CEO Juha Yrjänheikki and COO Laurent Decory, was aimed at strengthening partnerships and exploring potential investment opportunities in one of the world’s largest pharmaceutical markets. During the visit, the Aurealis Therapeutics team had the pleasure

Read More »

Interview with Hanna-Riikka Kärkkäinen Head of Quality and Regulatory Affairs at Aurealis Therapeutics | Professional career, AUP-16 PRIME designation, FDA Advice & more

What was the journey that took Hanna-Riikka Kärkkäinen to her current role as Head of Quality and Regulatory Affairs? What does having the PRIME designation for AUP-16 mean? What was the result of the FDA Advice that Aurealis had with respect of AUP-16? How are the preparations to take AUP-16 to the world moving forward? We discussed this and more in the interview with Hanna-Riikka so let’s get started. Could

Read More »